Ninety-eight ALK-positive patients with advanced NSCLC were retrospectively studied for their clinical response to crizotinib after excluding patients with early staging, unacceptable crozotinib toxicitiesor unclear clinical history, as well as patients without crizotinib treatment (Supplementary Figure 1). The gene discussed is ALK; the disease is non-small cell lung carcinoma.